Interstitial Lung Disease in a Patient Treated with Denosumab

Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significant interstitial lung disease likely related to denosumab.

Download Full-text

Elotuzumab-induced interstitial lung disease: the first case report

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy049 ◽

2018 ◽

Vol 48 (5) ◽

pp. 491-494 ◽

Cited By ~ 3

Author(s):

Toru Tanaka ◽

Yoshinobu Saito ◽

Nariaki Kokuho ◽

Hideto Tamura ◽

Yasuhiro Terasaki ◽

...

Keyword(s):

Case Report ◽

Interstitial Lung Disease ◽

Lung Disease ◽

First Case

Download Full-text

Case Report: Rapidly Progressive Interstitial Lung Disease in A Pregnant Patient With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

Frontiers in Immunology ◽

10.3389/fimmu.2021.625495 ◽

2021 ◽

Vol 12 ◽

Author(s):

Cuihong Chen ◽

Yulan Chen ◽

Qin Huang ◽

Qiu Hu ◽

Xiaoping Hong

Keyword(s):

Case Report ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Pregnant Patient ◽

Amyopathic Dermatomyositis ◽

Clinically Amyopathic Dermatomyositis ◽

First Case ◽

Immunosuppressant Regimen ◽

Present Case Study

Dermatomyositis occurs extremely rarely during pregnancy. A number of studies in the published literature have documented how the outcome of pregnancy is poor for both mother and fetus. The present case study reports on a patient who was diagnosed with clinically amyopathic dermatomyositis complicated by interstitial lung disease during pregnancy, and was successfully treated with a combined immunosuppressant regimen. To the best of the authors’ knowledge, this is the first case study detailing how a pregnant woman with clinically amyopathic dermatomyositis with positive anti-melanoma differentiation-associated gene 5 antibody achieved complete remission after early intervention of combined immunosuppressive therapy without residual pulmonary interstitial changes.

Download Full-text

Acceleration of interstitial lung disease induced by raltitrexed

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155219887213 ◽

2019 ◽

Vol 26 (5) ◽

pp. 1241-1243 ◽

Cited By ~ 1

Author(s):

Sarah Howlett ◽

Raminder Aul ◽

Mark Hill ◽

David J Pinato

Keyword(s):

Case Report ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Thymidylate Synthase ◽

Colorectal Adenocarcinoma ◽

Preoperative Staging ◽

Rapid Progression ◽

Lung Function Tests ◽

Clinical Pattern ◽

Significant Acceleration

Introduction Raltitrexed is a folate analogue, which selectively inhibits thymidylate synthase, used in the treatment of colorectal carcinoma. Common side effects include asthenia and gastrointestinal and haematological toxicities. Case report We present the case of a 74-year-old gentleman with incidental mild interstitial lung disease on preoperative staging CT Chest who developed acute breathlessness whilst undergoing adjuvant raltitrexed treatment for a completely excised colorectal adenocarcinoma. Management and outcome Discontinuation of raltitrexed and a course of steroid therapy resulted in resolution of symptoms, mirrored by an improvement in lung function tests. Discussion The clinical pattern of rapid progression with steroid response highlights the potential for significant acceleration of interstitial lung disease by raltitrexed.

Download Full-text

Is the interstitial lung disease induced by trastuzumab? Case report and literature review

Journal of Clinical Pharmacy and Therapeutics ◽

10.1111/jcpt.13118 ◽

2020 ◽

Vol 45 (5) ◽

pp. 1183-1186

Author(s):

Ziqi Ye ◽

Jie Chen ◽

Ming Chen ◽

Jiaying Wu

Keyword(s):

Case Report ◽

Interstitial Lung Disease ◽

Literature Review ◽

Lung Disease

Download Full-text

Plaque erosion causing ST-elevation myocardial infarction after consumption of cannabis and N2O in a 27-year old man: a case report

BMC Cardiovascular Disorders ◽

10.1186/s12872-021-01953-3 ◽

2021 ◽

Vol 21 (1) ◽

Cited By ~ 1

Author(s):

Sarah Bär ◽

Fabien Praz ◽

Lorenz Räber

Keyword(s):

Myocardial Infarction ◽

Case Report ◽

Adverse Effects ◽

Cardiovascular Effects ◽

Drug Eluting Stent ◽

Culprit Lesion ◽

Vascular Events ◽

The Public ◽

Plaque Erosion ◽

First Case

Abstract Background The recreational drugs cannabis and nitrous oxide (N2O) are known for pro-atherogenic effects and are associated with an elevated risk of myocardial infarction. These cardiovascular effects might be underestimated by the public. Culprit-lesion composition of myocardial infarctions associated with cannabis and N2O has been unknown so far. This case report aims to raise the awareness of the adverse cardiovascular effects of cannabis and N2O and reports, for the first time, optical coherence tomography (OCT) findings of the culprit lesion. Case presentation This is a case report of a 27-year old man with anterior ST-segment-elevation myocardial infarction (STEMI) after intoxication with cannabis and N2O. Coronary angiography and OCT revealed plaque erosion with subsequent subtotal thrombotic occlusion of the left anterior descending artery that was successfully treated with 1 drug-eluting stent. The patient was symptom free at 6 months follow-up and had been able to abstain from drug consumption. Conclusions This is the first case to demonstrate the association between cannabis and N2O abuse and plaque erosion on OCT in a young man with STEMI. In contrast to smoking, whose adverse effects are well-known, the cardiovascular effects of cannabis and N2O might be underestimated. These adverse effects should gain more awareness in the public to prevent early vascular events in young adults.

Download Full-text